Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Millennium Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier:
NCT01193244
First received: August 31, 2010
Last updated: July 1, 2013
Last verified: July 2013

August 31, 2010
July 1, 2013
October 2010
August 2014   (final data collection date for primary outcome measure)
  • Radiographic progression-free survival (rPFS) [ Time Frame: Day 1 to radiographic disease progression or death ] [ Designated as safety issue: No ]
    Time from randomization to radiographic disease progression or death from any cause, whichever occurs first
  • Overall survival (OS) [ Time Frame: Time from date of patient randomization to the date of patient death due to any cause ] [ Designated as safety issue: No ]
    Overall survival
  • To determine if orteronel plus prednisone improves radiographic progression-free survival (rPFS) [ Time Frame: Day 1 to radiographic disease progression or death ] [ Designated as safety issue: No ]
    Time from randomization to radiographic disease progression or death from any cause, whichever occurs first
  • To determine if orteronel plus prednisone improves overall survival (OS) [ Time Frame: Time from date of patient randomization to the date of patient death due to any cause ] [ Designated as safety issue: No ]
    Overall survival
Complete list of historical versions of study NCT01193244 on ClinicalTrials.gov Archive Site
  • 50% prostate specific antigen (PSA) response at 12 weeks [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    50% PSA response at 12 weeks
  • Changes in circulating tumor cell (CTC) counts [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
    Favorable changes in CTC levels at 24 weeks
  • Time to pain progression [ Time Frame: From randomization to the end of treatment ] [ Designated as safety issue: No ]
    Time to pain progression as measured by worst pain item in the Brief Pain Inventory-Short Form (BPI-SF) and changes in opioid analgesic use, if any
  • To determine if orteronel plus prednisone improves 50% prostate specific antigen (PSA) response at 12 weeks [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    50% PSA response at 12 weeks
  • To evaluate changes in circulating tumor cell (CTC) counts [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
    Favorable changes in CTC levels at 24 weeks
  • To evaluate whether orteronel improves time to pain progression [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    Time to pain progression as measured by worst pain item in the Brief Pain Inventory-Short Form (BPI-SF) and changes in opioid analgesic use, if any
Not Provided
Not Provided
 
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel Plus Prednisone With Placebo Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer

This is a randomized, double-blind, multicenter, phase 3 study evaluating orteronel (TAK-700) plus prednisone compared with placebo plus prednisone in the treatment of men with progressive, chemotherapy-naive, metastatic, castration-resistant prostate cancer (mCRPC)

Not Provided
Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Prostate Cancer
  • Drug: Orteronel + prednisone
    Orteronel and prednisone will be administered orally twice a day continuously throughout the study. Patients will also receive concomitant gonadotropin-releasing hormone (GnRH) analogue therapy unless they have previously undergone orchiectomy and have a testosterone concentration of <50 ng/dL.
  • Drug: Placebo + prednisone
    Placebo and prednisone will be administered orally twice a day continuously throughout the study. Additionally, all patients will receive concomitant gonadotropin-releasing hormone (GnRH) analogue therapy unless they have previously undergone orchiectomy and a testosterone concentration of <50 ng/dL.
  • Experimental: Orteronel + prednisone
    Intervention: Drug: Orteronel + prednisone
  • Placebo Comparator: Placebo + prednisone
    Intervention: Drug: Placebo + prednisone
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
1454
September 2014
August 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

Each patient must meet all of the following inclusion criteria:

  • Voluntary written consent
  • Male patients 18 years or older
  • Histologically or cytologically confirmed diagnosis of prostate adenocarcinoma
  • Radiograph-documented metastatic disease
  • Progressive disease
  • Prior surgical castration or concurrent use of an agent for medical castration
  • Either absence of pain or pain not requiring use of any opioid or narcotic analgesia in the 2 weeks prior to study entry
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
  • Even if surgically sterilized, patients must practice effective barrier contraception during the entire study treatment and for 4 months after the last dose of study drug, OR abstain from heterosexual intercourse
  • Meet screening laboratory values as specified in protocol
  • Stable medical condition

Exclusion Criteria:

Patients meeting any of the following exclusion criteria are not to be enrolled in the study:

  • Known hypersensitivity to orteronel, prednisone or gonadotropin-releasing hormone (GnRH) analogue
  • Received prior therapy with orteronel, aminoglutethimide, ketoconazole or abiraterone
  • Received antiandrogen therapy within 6 weeks for bicalutamide and 4 weeks for all others prior to first dose of study drug
  • Continuous daily use of oral prednisone or oral dexamethasone for more than 14 days within 3 months prior to study
  • Received prior chemotherapy for prostate cancer with exception of neoadjuvant/adjuvant therapy as part of initial primary treatment for local disease that was completed 2 or more years prior to screening
  • Exposure to radioisotope therapy within 4 weeks of receiving first dose of study drug; exposure to external beam radiation within 2 weeks of start of screening until receiving the first dose of study drug
  • Documented central nervous system metastases
  • Treatment with any investigational compound within 30 days prior to first dose of study drug
  • Current spinal cord compression, bilateral hydronephrosis or current bladder neck outlet obstruction
  • Diagnosis or treatment of another malignancy within 2 years preceding first dose of study drug except nonmelanoma skin cancer or in situ malignancy completely resected
  • Uncontrolled cardiovascular condition as specified in study protocol
  • Known history of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C
  • Unwilling or unable to comply with protocol
  • Uncontrolled nausea, vomiting or diarrhea
  • Known gastrointestinal disease or procedure that could interfere with oral absorption or tolerance of orteronel
Male
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States,   Australia,   Belgium,   Canada,   Czech Republic,   Estonia,   Finland,   France,   Greece,   Hungary,   Italy,   Latvia,   Netherlands,   New Zealand,   Poland,   Singapore,   Slovakia,   Turkey
 
NCT01193244
C21004, 2010-018661-35
Yes
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc.
Not Provided
Study Director: Medical Monitor Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc.
July 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP